A 2-part, Randomized, Double-blind, Placebo-controlled, Sequential Group, Dose-escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Oral Doses of GLPG2737 in Healthy Male Subjects

Trial Profile

A 2-part, Randomized, Double-blind, Placebo-controlled, Sequential Group, Dose-escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Oral Doses of GLPG2737 in Healthy Male Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 30 Jan 2018

At a glance

  • Drugs GLPG 2737 (Primary)
  • Indications Cystic fibrosis
  • Focus Adverse reactions
  • Sponsors Galapagos NV
  • Most Recent Events

    • 01 Dec 2016 New trial record
    • 28 Nov 2016 According to a Galapagos NV media release, top-line results are expected in the second quarter of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top